DEC 10, 2016 11:00 AM PST

New Immunotherapy Prevents Relapse for Leukemia Survivors

WRITTEN BY: Kara Marker
For high-risk cancer patients with acute myeloid leukemia (AML), oncologists are interested in supplementing bone marrow transplants with a new, experimental treatment with genetically engineered T cells. The first study was conducted in a small number of patients, but scientists believe that there will soon be more studies like it done due to the successful results.
 A high power view of AML with multilineage dysplasia. Source: American Society of Hematology
From the Fred Hutchison Cancer Research Center, scientists took in 12 patients with high-risk AML who had received a bone marrow transplant that put them in remission. The patients were all considered to be high-risk due to genetic factors or other disease characteristics that reduced the chance of remaining in remission following a bone marrow transplant. Following the transplant procedure, researchers continued with a treatment of genetically engineered T cells.
 
T cells from the treatment were extracted from each patient’s own transplant donor. After extraction, the cells were genetically engineered to express receptors on their cell surface that recognize very specifically a target molecule, called WT1. This molecule is much more highly concentrated in leukemia cells than non-cancerous cells, which helps the T cells distinguish tumor cells from healthy cells.
 
After a median follow-up of time of two years, all 12 of the study’s participants were still in remission. The combination of a bone marrow transplant and T cell therapy is what study leader Dr. Aude Chapuis believes is the secret to the success of the treatment. It “might actually be helping patients who have a high risk of relapsing,” she explained.
 
The findings observed in this study differ from what scientists saw in previous studies where AML patients received a transplant but no genetically engineered T cells. Instead of remaining in remission, around 25 percent of the transplant-only patients relapsed within 10 months.
 
Chapuis’s study was just the first trial using this strategy. Their experimental group was indeed small, but studying high-risk group of AML patients provided them the most extreme case to prove that their treatment combination would be effective.
 
Chapuis, who treats cancer patients at Seattle Cancer Care Analysis, says that her source of inspiration for the work that she does is the patients she sees everyday undergoing bone marrow transplants. “I’m always horrified by the intense treatment that we inflict on bone marrow transplant patients and the hardship that we make them go through,” Chapuis said. “I really think we can do better. That’s why I’m doing this.”
 

 
Source: Fred Hutchison Cancer Research Center
 
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUN 04, 2018
Immunology
JUN 04, 2018
Asthma and Flu Make A Deadly Combination
When someone with a cold or the flu also has an asthma attack, the situation can become life-threatening very quickly. From the University of Montreal, sci...
JUN 14, 2018
Health & Medicine
JUN 14, 2018
Beware of Hotel Room Germs
Recently the CDC came out with a study that showed nearly 1/3 of swimming-related illnesses from 2000-2014 could be traced back to pathogens found in hotel...
JUN 20, 2018
Immunology
JUN 20, 2018
Immune System Accidentally Allows Meningitis Brain Infection
Several immune cells help fungi infect the brain and cause meningitis when they should be doing the exact opposite. From the University of Sydney, research...
JUL 04, 2018
Neuroscience
JUL 04, 2018
Can Herpes Raise Your Risk for Alzheimer's?
Alzheimer's disease has no cure and no well-understood cause. Experts know that tangles of tau protein that develop in the brain impact memory and func...
JUL 05, 2018
Health & Medicine
JUL 05, 2018
Is Testing Everyone for Hep C Necessary?
Cases of Hepatitis C, known as Hep C or HCV, are on the rise. In the United States, the CDC reports that there were approximately 3,000 new cases of hepati...
AUG 04, 2018
Immunology
AUG 04, 2018
Infant's Innate Immune Response
An infant's innate immune response develops from fetus to birth, but it may not be as "immature" as previously thought....
Loading Comments...